ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)GlobeNewsWire • 05/18/20
ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/07/20
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/11/20
ChemoCentryx Brings Hope To Vasculitis Patients, Steroid Therapy Can Play A Smaller RoleSeeking Alpha • 11/27/19
ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated VasculitisGlobeNewsWire • 11/25/19
Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)GlobeNewsWire • 11/05/19
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/06/19
InflaRx Tanks 91.79% As IFX-1 Phase II Trial Flops, Provides Bargain Buy For Competitor ChemoCentryxSeeking Alpha • 06/08/19